The acquisition of a drug factory in Bayer, Germany, by a Chinese company will be used in the production of the new crown vaccine

Pharmaceutical Network December 22 - Bayer and China Pharmaceutical Biology announced on the 21st that they have reached an acquisition deal.
under the agreement, Pharmaceuticals will buy Bayer's biopharmaceous plant in Wuppertal, Germany, for about 150 million euros to produce active ingredients in the new crown vaccine and other biologics.
,000-based Bayer in Leverkusen, Germany, is one of the world's largest companies in the healthcare and agriculture sectors.
Pharmaceuticals, which has three operating bases in Shanghai, Wuxi and Suzhou, China, and is listed in Hong Kong, is an open biopharmaceutical technology platform that provides end-to-end research and development services to biopharmaceutical and biotechnology companies worldwide.
acquisition is the second time this year that Pharmaceuticals has acquired a pharmaceutical plant in Germany.
completed its acquisition of Bayer's biologics plant (DP7) in Leverkusen, Germany, in April.
Pharmaceutical Biologics said on the 21st, the acquisition of the biopharmaceuser plant (MFG19) area of 30,000 square meters, including 3 1000 liter irrigation lines and 6 2000 liters of flow plus production lines, as well as independent downstream facilities, will further enhance the global supply capacity of Pharmaceuticals for new crown vaccines and other biological drugs.
MFG19 and DP7 plants are expected to be in production by 2021, providing strong support for the European production supply chain for Pharmaceuticals.
and Pharmaceuticals said the deal was subject to regulatory approval and was expected to close in the first half of 2021.
(Complete)